-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22

Benzinga·10/23/2026 12:24:51
Listen to the news
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.